Literature DB >> 20066495

Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.

Allan Meldgaard Lund1, Flemming Skovby, Helle Vestergaard, Mette Christensen, Ernst Christensen.   

Abstract

Evidence-based guidelines for monitoring patients with disorders in fatty acid oxidation (FAO) are lacking, and most protocols are based on expert statements. Here, we describe our protocol for Danish patients. Clinical monitoring is the most important measure and has the main aims of checking growth, development and diet and of bringing families to the clinic regularly to remind them of their child's risk and review how they cope and adjust, e.g. to an acute intercurrent illness. Most of these measures are simple and can be carried out during a routine out-patient visit; we seldom do more complicated assessments by a neuropsychologist, speech therapist, or physical and occupational therapists. Paraclinical measurements are not used for short-chain and medium-chain disorders; electrocardiography (including 24 h monitoring) and echocardiography are done for most patients with long-chain and carnitine transporter deficiencies. Eye examination is done in all, and liver ultrasonography in some patients with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase/tri-functional protein (LCHAD/TFP) deficiencies. Biochemical follow-up includes determination of free carnitine and acylcarnitines. Free carnitine is measured to monitor carnitine supplementation in patients with multiple acyl-coenzyme A dehydrogenase deficiency (MADD) and carnitine transporter deficiency (CTD) and to follow metabolic control and disclose deficiency states in other FAO disorders. We are evaluating long-chain acylcarnitines in patients with long-chain disorders; so far there does not seem to be any clear-cut benefit in following these levels. An erythrocyte fatty acid profile is done in patients with long-chain disorders to test for essential fatty acid and docosahexanoic acid (DHA) deficiencies. The measurement of creatine kinase is helpful in long-chain disorders. Ongoing follow-up and education of the patient is important throughout life to prevent disease morbidity or death from metabolic crises.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066495     DOI: 10.1007/s10545-009-9000-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

Review 1.  Clinical and biochemical features of fatty acid oxidation disorders.

Authors:  P Rinaldo; K Raymond; A al-Odaib; M J Bennett
Journal:  Curr Opin Pediatr       Date:  1998-12       Impact factor: 2.856

2.  Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations.

Authors:  Leigh Waddell; Veronica Wiley; Kevin Carpenter; Bruce Bennetts; Lyn Angel; Brage S Andresen; Bridget Wilcken
Journal:  Mol Genet Metab       Date:  2005-11-15       Impact factor: 4.797

Review 3.  Carnitine deficiency disorders in children.

Authors:  Charles A Stanley
Journal:  Ann N Y Acad Sci       Date:  2004-11       Impact factor: 5.691

4.  Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.

Authors:  Melanie B Gillingham; Jonathan Q Purnell; Julia Jordan; Diane Stadler; Andrea M Haqq; Cary O Harding
Journal:  Mol Genet Metab       Date:  2006-09-22       Impact factor: 4.797

Review 5.  Disorders of mitochondrial fatty acyl-CoA beta-oxidation.

Authors:  R J Wanders; P Vreken; M E den Boer; F A Wijburg; A H van Gennip; L IJlst
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

6.  Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase defiency.

Authors:  J L Van Hove; S G Kahler; M D Feezor; J P Ramakrishna; P Hart; W R Treem; J J Shen; D Matern; D S Millington
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

7.  Plasma and erythrocyte fatty acid concentrations in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  A M Lund; M A Dixon; P Vreken; J V Leonard; A A M Morris
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 8.  Mitochondrial fatty-acid oxidation disorders.

Authors:  Michelle Kompare; William B Rizzo
Journal:  Semin Pediatr Neurol       Date:  2008-09       Impact factor: 1.636

9.  A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.

Authors:  Georgianne L Arnold; Johan Van Hove; Debra Freedenberg; Arnold Strauss; Nicola Longo; Barbara Burton; Cheryl Garganta; Can Ficicioglu; Stephen Cederbaum; Cary Harding; Richard G Boles; Dietrich Matern; Pranesh Chakraborty; Annette Feigenbaum
Journal:  Mol Genet Metab       Date:  2009-01-20       Impact factor: 4.797

Review 10.  Tolerance to fast: rational and practical evaluation in children with hypoketonaemia.

Authors:  J H Walter
Journal:  J Inherit Metab Dis       Date:  2009-03-04       Impact factor: 4.982

View more
  9 in total

1.  Growth in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency.

Authors:  C Bieneck Haglind; M Halldin Stenlid; S Ask; J Alm; A Nemeth; Uv Döbeln; A Nordenström
Journal:  JIMD Rep       Date:  2012-07-06

2.  Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fast.

Authors:  C Bieneck Haglind; A Nordenström; S Ask; U von Döbeln; J Gustafsson; M Halldin Stenlid
Journal:  J Inherit Metab Dis       Date:  2014-08-21       Impact factor: 4.982

3.  Cyclic vomiting syndrome masking a fatal metabolic disease.

Authors:  Marianne Fitzgerald; Ellen Crushell; Caroline Hickey
Journal:  Eur J Pediatr       Date:  2012-10-11       Impact factor: 3.183

4.  Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature.

Authors:  Isidro Vitoria; Elena Martín-Hernández; Luis Peña-Quintana; María Bueno; Pilar Quijada-Fraile; Jaime Dalmau; Sofia Molina-Marrero; Belén Pérez; Begoña Merinero
Journal:  JIMD Rep       Date:  2015-01-23

5.  Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD.

Authors:  Gabriela Elizondo; Dietrich Matern; Jerry Vockley; Cary O Harding; Melanie B Gillingham
Journal:  Mol Genet Metab       Date:  2020-09-06       Impact factor: 4.797

6.  Infant with hepatomegaly and hypoglycemia: A setting for fatty acid oxidation defects.

Authors:  Aathira Ravindranath; Gautham Pai; Anshu Srivastava; Ujjal Poddar; Surender Kumar Yachha
Journal:  Indian J Gastroenterol       Date:  2017-10-26

7.  Multiple Acyl-CoA Dehydrogenation Deficiency (Glutaric Aciduria Type II) with a Novel Mutation of Electron Transfer Flavoprotein-Dehydrogenase in a Cat.

Authors:  Shoichi Wakitani; Shidow Torisu; Taiki Yoshino; Kazuhisa Hattanda; Osamu Yamato; Ryuji Tasaki; Haruo Fujita; Koichiro Nishino
Journal:  JIMD Rep       Date:  2013-10-20

Review 8.  Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.

Authors:  Suzan J G Knottnerus; Jeannette C Bleeker; Rob C I Wüst; Sacha Ferdinandusse; Lodewijk IJlst; Frits A Wijburg; Ronald J A Wanders; Gepke Visser; Riekelt H Houtkooper
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

9.  Need for strict clinical management of patients with carnitine palmitoyltransferase II deficiency: Experience with two cases detected by expanded newborn screening.

Authors:  Ryosuke Bo; Ikuma Musha; Kenji Yamada; Hironori Kobayashi; Yuki Hasegawa; Hiroyuki Awano; Masato Arao; Toru Kikuchi; Takeshi Taketani; Akira Ohtake; Seiji Yamaguchi; Kazumoto Iijima
Journal:  Mol Genet Metab Rep       Date:  2020-05-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.